Skip to main content
SpringerLink
Log in

Parkinson disease

Calcium channel blockers and Parkinson disease

  • News & Views
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

Substantial progress has been made over the past four decades in treating the symptoms of Parkinson disease, but treatments that slow its inexorable progression have remained tantalizingly out of reach. New research raises hopes that a means might have been found to safely and effectively slow progression of Parkinson disease and delay its clinical emergence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Olanow, W. C. et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361, 1268–1278 (2009).

    Article  CAS  Google Scholar 

  2. Wider, C. & Wszolek, Z. K. Clinical genetics of Parkinson's disease and related disorders. Parkinsonism Relat. Disord. 13 (Suppl. 3), S229–S232 (2007).

    Article  Google Scholar 

  3. Tanner, C. M. et al. Occupation and risk of parkinsonism: a multicenter case-control study. Arch. Neurol. 66, 1106–1113 (2009).

    Article  Google Scholar 

  4. DeCuypere, M., Lu, Y., Miller, D. D. & LeDoux, M. S. Regional distribution of tetrahydroisoquinoline derivatives in rodent, human, and Parkinson's disease brain. J. Neurochem. 107, 1398–1413 (2008).

    Article  CAS  Google Scholar 

  5. Olanow, W. C. & Prusiner, S. B. Is Parkinson's disease a prion disorder? Proc. Natl Acad. Sci. USA 106, 12571–12572 (2009).

    Article  CAS  Google Scholar 

  6. Jang, H. et al. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc. Natl Acad. Sci. USA 106, 14063–14068 (2009).

    Article  CAS  Google Scholar 

  7. Ritz, B. et al. L-type calcium channel blockers and Parkinson's disease in Denmark. Ann. Neurol. doi: 10.1002/ana.21937.

  8. Surmeier, D. J., Guzman, J. N. & Sanchez-Padilla, J. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease. Cell Calcium doi: 10.1016/j.ceca.2009.12.003.

  9. Guzman, J. N., Sanchez-Padilla, J., Chan, C. S. & Surmeier, D. J. Robust pacemaking in substantia nigra dopaminergic neurons. J. Neurosci. 29, 11011–11019 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Tennessee Health Science Center, 855 Monroe Avenue, Memphis, 38163, TN, USA

    Ronald F. Pfeiffer

Authors
  1. Ronald F. Pfeiffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

R. F. Pfeiffer has received honoraria from Boehringer-Ingelheim, GlaxoSmithKline, Novartis and Teva for lectures and honoraria from Boehringer-Ingelheim, Genactis, Ipsen, Kyowa, Schlesinger Associates, Solvay and Theravance for consulting. He has also received research funding from Boehringer-Ingelheim, Eisai, Kyowa, Novartis, Santhera and Schwarz and honoraria from the Michael J Fox Foundation, Northwestern University and the Parkinson Study Group for acting as a clinical trial site investigator.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pfeiffer, R. Calcium channel blockers and Parkinson disease. Nat Rev Neurol 6, 188–189 (2010). https://doi.org/10.1038/nrneurol.2010.31

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2010.31

  • Springer Nature Limited

This article is cited by

Search

Navigation